CHCWM – Cancer & Hematology Centers of West Michigan

TWT-101 (Treadwell Therapeutics, Inc.)

A First In-Human, Phase I/II Study of CFI-402411, Hematopoietic Progenitor Inase-1 (HPK1) Inhibitor, As A Single Agent and In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies